Clinical Trial Update: 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

View source ↗

Summary

A completed study used Zirconium-89 labeled trastuzumab PET to image the effect of an HSP90 inhibitor in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 89Zr-trastuzumab (zirconium-89-labeled trastuzumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Breast Cancer | Status: COMPLETED